When a younger clock may track disease recovery
Human trial reanalysisProteomic aging-clock estimates in previously collected clinical samples.
A younger-looking measurement is a starting point, not a finish line.

Before choosing an assay, write down what the tissue should do better. The answer might be a reproducible performance measure, a repair outcome, or a specific cellular task. Avoid choosing the definition of success after seeing which marker changes.
Record target engagement, molecular state, cell identity, and tissue performance separately. A positive finding in one category must not erase a null result in another. The separation also makes disagreements more informative.
A useful brief ends with the missing observation that would change the decision. It should not end with an impressive percentage detached from its population, assay, and comparator.
Proteomic aging-clock estimates in previously collected clinical samples.
Blood NAD metabolites; hearing and physical-performance outcomes.
Original publisher links and access limits are included in every brief. Artwork is conceptual, not a reproduction of study figures.